A Phase 1 Study of LY2874455 in Participants With Advanced Cancer
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The study is to determine the recommended Phase 2 regimen of study drug that may be safely
administered to participants with advanced and or metastatic cancer. The study consists of
two parts: a dose escalation and a dose confirmation.